• Last updated：2024-08-13
• Count Views：1225

The Health Technology Assessment International (HTAi) was established in 2003 as a prominent organization in the field of health technology assessment. It serves as a crucial academic and professional entity, providing decision-makers with evidence-based perspectives on healthcare resource utilization from a diverse range of scientific viewpoints. HTAi boasts a membership spanning over 65 countries across six continents, including 82 organizations and more than 2500 individual members.
Every year, the Center for Drug Evaluation (CDE) is invited by HTAi to participate in its conferences. CDE representatives have served as speakers, sharing Taiwan's research experiences, and have also been panelists in numerous workshops.

2023

The 23rd HTAi Annual Meeting took place from June 24 to 28, 2023, in Adelaide, Australia, attended by Director Li-Ying Huang and Researcher Mei-Chi Lai.
Director Huang was re-elected in 2023 as a board member of the HTAi Council, enabling her to stay abreast of the latest developments and focus areas in international health technology assessment. This role allows her to contribute Taiwan's experiences and help shape the global direction of health technology assessment, thereby expanding Taiwan's presence in the Asian network of health technology assessment. The theme of the 23rd HTAi Annual Meeting was "The road to policy and clinical integration," focusing on challenges such as adapting to innovation and emerging technologies, balancing stakeholder interests and data demands, meeting public expectations, and achieving patient-centered healthcare systems. Key topics included: (1) Fast-Tracking Clinical Innovation: The Balance of Speed and Rigour, (2) Public Confidence in Healthcare Decision-Making, and (3) Running Around in Circles; Time for Real Collaboration between Regulators, HTA Bodies and Clinicians. Director Huang was invited to speak at two HTAi Working Group sessions and participate in two panels, sharing Taiwan's experiences in health technology assessment.

Since 2013, HTAi has organized the HTAi Asia Policy Forum, providing a platform for official and industry stakeholders in Asia to converse, discuss, and debate. In addition to the annual HTAi Global Policy Forum held in North America or Europe, HTAi hosts an Asia Policy Forum in various Asian locations each year to incorporate Asian perspectives. This year marks the 10th anniversary of the forum, and for the first time, Taiwan successfully hosted the event. The theme of this year's HTAi Asia Policy Forum was "Being Bold – How HTA can Foster Innovation in the Asia Region." Approximately 60 representatives from 14 countries including Japan, Singapore, South Korea, New Southbound Policy countries, Australia, Canada, and the United States attended the conference, including HTAi President Dr. Rabia Sucu and HTAi Asia Forum Chair Dr. Guy Maddern. Director General Chung-Liang Shih of the National Health Insurance Administration, Ministry of Health and Welfare, and Deputy Executive Director Shou-Yu Lin of the Center for Drug Evaluation were invited to deliver speeches at the conference.

2022

In 2022, the 22nd HTAi Annual Meeting focused on "Lifecycle Approach: Coming Together to Make It Happen." This theme addressed challenges such as innovation in new technologies, diverse stakeholder interests and data requirements, public expectations, and achieving patient-centered healthcare systems. The lifecycle approach in Health Technology Assessment (HTA) was discussed as a method for evaluating the value of pharmaceuticals, medical devices, and other healthcare services from pre-market stages through to post-market phases and disinvestment. HTAi 2022 provided a global platform to explore the impacts of adopting the HTA lifecycle approach, deepen awareness, enhance understanding of appropriate methods and processes, and strengthen connections among stakeholders while prioritizing activities. Therefore, key topics at the conference included: (1) Adopting a Lifecycle Approach in HTA: Consequences for Priority-Setting and International Collaboration, (2) Public Confidence in Healthcare Decision-Making, and (3) Running Around in Circles; Time for Real Collaboration between Regulators, HTA Bodies and Clinicians. Director Li-Ying Huang, as invited by the conference, served as a speaker in one HTAi Working Group session and participated in three panels, sharing Taiwan's experiences in health technology assessment.

2021

The theme of the 21st HTAi Annual Meeting was "Innovation Through HTA." In the face of advancements in new drugs and technologies such as disruptive technologies, cell and gene therapies, and precision medicine, decision-makers are under pressure to not only meet the basic needs of healthcare systems but also provide innovative medical services to meet public expectations. How should traditional health technology assessment (HTA) respond to this challenge? Therefore, key topics at the conference included: (1) HTA in a changing evidence eco-system, (2) Patient being at the Heart of the Innovation Pathway, and (3) Innovating HTA to support new interventions. Director Li-Ying Huang was invited by the conference to participated as a panelist in the HTAi panel: HTAi-ISPOR Task Force Principles for deliberative processes in health technology assessment, sharing Taiwan's experiences in health technology assessment.